NCT03533101View on ClinicalTrials.gov

Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 25, 2018

Primary Completion Date

May 15, 2019

Study Completion Date

June 15, 2019

Conditions
Cytokine Release SyndromeStem Cell Transplant Complications
Interventions
DRUG

Tocilizumab

IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome

Trial Locations (1)

64460

Hospital Universitario Dr. Jose E Gonzalez UANL, Monterrey

All Listed Sponsors
lead

Hospital Universitario Dr. Jose E. Gonzalez

OTHER

NCT03533101 - Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation | Biotech Hunter | Biotech Hunter